February 20, 2026 — Leads & Copy — Exact Sciences Corporation stockholders have approved the proposed acquisition of the company by Abbott, according to preliminary results from a special meeting held today.
More than 99% of the votes cast were in favor of the transaction, representing about 67% of Exact Sciences’ total outstanding shares as of January 9, 2026, the record date for the meeting. Exact Sciences (NASDAQ: EXAS) will report the final voting results in a Current Report on Form 8-K filed with the SEC.
The acquisition is expected to close before the end of the second calendar quarter of 2026, pending the satisfaction or waiver of the remaining closing conditions. Under the agreement with Abbott (NYSE: ABT), Exact Sciences’ stockholders will receive $105 in cash for each share of Exact Sciences common stock they owned immediately before the deal’s completion, excluding interest and applicable withholding taxes.
Exact Sciences is a provider of cancer screening and diagnostic tests. Its portfolio includes brands like Cologuard and Oncotype DX, as well as solutions such as Cancerguard for multi-cancer early detection and Oncodetect for molecular residual disease and recurrence monitoring. The company continues to invest in cancer diagnostics.
Oncodetect and Oncotype DX are trademarks of Genomic Health, Inc., an Exact Sciences subsidiary. Cancerguard, Cologuard and Exact Sciences are trademarks of Exact Sciences Corporation. Cologuard, Cancerguard and Oncodetect are currently available in the United States.
Source: Exact Sciences
